RS55165B1 - Indazolil triazol derivati kao irak inhibitori - Google Patents
Indazolil triazol derivati kao irak inhibitoriInfo
- Publication number
- RS55165B1 RS55165B1 RS20160779A RSP20160779A RS55165B1 RS 55165 B1 RS55165 B1 RS 55165B1 RS 20160779 A RS20160779 A RS 20160779A RS P20160779 A RSP20160779 A RS P20160779A RS 55165 B1 RS55165 B1 RS 55165B1
- Authority
- RS
- Serbia
- Prior art keywords
- triazole derivatives
- irak inhibitors
- indazolyl
- indazolyl triazole
- irak
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061424890P | 2010-12-20 | 2010-12-20 | |
EP10195867 | 2010-12-20 | ||
PCT/EP2011/073015 WO2012084704A1 (en) | 2010-12-20 | 2011-12-16 | Indazolyl triazole derivatives as irak inhibitors |
EP11801711.0A EP2655357B1 (en) | 2010-12-20 | 2011-12-16 | Indazolyl triazole derivatives as irak inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
RS55165B1 true RS55165B1 (sr) | 2017-01-31 |
Family
ID=43838132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20160779A RS55165B1 (sr) | 2010-12-20 | 2011-12-16 | Indazolil triazol derivati kao irak inhibitori |
Country Status (24)
Country | Link |
---|---|
US (1) | US9073892B2 (sr) |
EP (1) | EP2655357B1 (sr) |
JP (1) | JP6007189B2 (sr) |
KR (1) | KR101842098B1 (sr) |
CN (1) | CN103429585B (sr) |
AR (1) | AR084507A1 (sr) |
AU (1) | AU2011347711B2 (sr) |
BR (2) | BR112013015460B1 (sr) |
CA (1) | CA2822166C (sr) |
EA (1) | EA023544B1 (sr) |
ES (1) | ES2592713T3 (sr) |
HK (1) | HK1191938A1 (sr) |
HR (1) | HRP20161127T1 (sr) |
HU (1) | HUE029617T2 (sr) |
IL (1) | IL226912A (sr) |
LT (1) | LT2655357T (sr) |
MX (1) | MX2013007149A (sr) |
PL (1) | PL2655357T3 (sr) |
PT (1) | PT2655357T (sr) |
RS (1) | RS55165B1 (sr) |
SG (1) | SG191205A1 (sr) |
SI (1) | SI2655357T1 (sr) |
WO (1) | WO2012084704A1 (sr) |
ZA (1) | ZA201305483B (sr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
EP2934517A4 (en) | 2012-12-20 | 2016-05-25 | Merck Sharp & Dohme | 4-SUBSTITUTED 2-PYRYDYLOXY-3-NITRILE OREXIN RECEPTOR ANTAGONISTS |
US9765057B2 (en) | 2012-12-20 | 2017-09-19 | Merck Sharp & Dohme Corp. | 3-ester-4 substituted orexin receptor antagonists |
RS56331B1 (sr) * | 2013-02-07 | 2017-12-29 | Merck Patent Gmbh | Derivati piridazinon-amida |
ES2639717T3 (es) * | 2013-02-07 | 2017-10-30 | Merck Patent Gmbh | Derivados de piridazinona macrocíclicos |
SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
JP2017505337A (ja) | 2014-01-10 | 2017-02-16 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Irak4阻害剤としてのインダゾール化合物 |
KR102392684B1 (ko) | 2014-01-13 | 2022-04-29 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 억제제로서의 바이시클릭 헤테로시클릴 유도체 |
US9932350B2 (en) | 2014-09-30 | 2018-04-03 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
EP3200788B1 (en) * | 2014-09-30 | 2019-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
US9943516B2 (en) | 2014-09-30 | 2018-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
EP3200787B1 (en) * | 2014-09-30 | 2019-09-04 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
WO2016096709A1 (en) | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
SG10201912656SA (en) | 2015-04-22 | 2020-02-27 | Rigel Pharmaceuticals Inc | Pyrazole compounds and method for making and using the compounds |
EP3288558B1 (en) | 2015-04-30 | 2022-05-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
EP3195865A1 (de) | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Kombinationen von irak4 inhibitoren und btk inhibitoren |
CA3016364A1 (en) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
SI3448846T1 (sl) | 2016-04-29 | 2021-09-30 | Bayer Pharma Aktiengesellschaft | Sinteza indazolov |
CU24593B1 (es) | 2016-04-29 | 2022-05-11 | Bayer Pharma AG | Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida |
MY199070A (en) | 2016-06-01 | 2023-10-12 | Bayer Pharma AG | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
IL293783B2 (en) | 2017-03-31 | 2024-01-01 | Aurigene Oncology Ltd | Compounds and preparations for the treatment of hematological disorders |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
IL295603B2 (en) | 2017-09-22 | 2024-03-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
BR112020007679A2 (pt) | 2017-10-19 | 2020-10-20 | Bayer Animal Health Gmbh | uso de pirrolidonas heteroaromáticas fundidas para tratamento e prevenção de doenças em animais. |
PL3704108T3 (pl) | 2017-10-31 | 2024-07-22 | Curis, Inc. | Inhibitor irak4 w połączeniu z inhibitorem bcl-2 do stosowania w leczeniu nowotworu złośliwego |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
AU2018396142A1 (en) | 2017-12-26 | 2020-07-16 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND THEIR USES |
GB201801226D0 (en) * | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
AU2019262195B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
WO2020165062A1 (en) * | 2019-02-11 | 2020-08-20 | Merck Patent Gmbh | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
MX2022002292A (es) | 2019-08-30 | 2022-06-02 | Rigel Pharmaceuticals Inc | Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones. |
CN114466844A (zh) | 2019-10-02 | 2022-05-10 | 康佳诺医疗科技发展有限公司 | N-(1h-咪唑-2-基)苯甲酰胺化合物及包含其作为活性成分的药物组合物 |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US20230034723A1 (en) * | 2019-10-31 | 2023-02-02 | Hoffmann-La Roche Inc. | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス, インコーポレイテッド | Irak分解剤およびそれらの使用 |
WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
KR102607237B1 (ko) * | 2023-06-07 | 2023-11-30 | 주식회사 젠센 | 신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1732004A (zh) * | 2002-10-24 | 2006-02-08 | 细胞基因公司 | 用jnk抑制剂治疗疼痛 |
US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
US20050090529A1 (en) * | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
EP1891051A2 (en) * | 2005-04-29 | 2008-02-27 | Celgene Corporation | Solid forms of 1-( 5-(ih-i , 2 , 4 -triazol- 5 -yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene |
MX2009013213A (es) * | 2007-06-08 | 2010-03-30 | Abbott Lab | Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa. |
-
2011
- 2011-12-16 ES ES11801711.0T patent/ES2592713T3/es active Active
- 2011-12-16 BR BR112013015460-8A patent/BR112013015460B1/pt active IP Right Grant
- 2011-12-16 PL PL11801711.0T patent/PL2655357T3/pl unknown
- 2011-12-16 MX MX2013007149A patent/MX2013007149A/es active IP Right Grant
- 2011-12-16 CA CA2822166A patent/CA2822166C/en active Active
- 2011-12-16 LT LTEP11801711.0T patent/LT2655357T/lt unknown
- 2011-12-16 BR BR122021014375-7A patent/BR122021014375B1/pt active IP Right Grant
- 2011-12-16 SG SG2013046586A patent/SG191205A1/en unknown
- 2011-12-16 WO PCT/EP2011/073015 patent/WO2012084704A1/en active Application Filing
- 2011-12-16 PT PT118017110T patent/PT2655357T/pt unknown
- 2011-12-16 SI SI201130961A patent/SI2655357T1/sl unknown
- 2011-12-16 HU HUE11801711A patent/HUE029617T2/en unknown
- 2011-12-16 AU AU2011347711A patent/AU2011347711B2/en active Active
- 2011-12-16 EP EP11801711.0A patent/EP2655357B1/en active Active
- 2011-12-16 EA EA201300730A patent/EA023544B1/ru not_active IP Right Cessation
- 2011-12-16 KR KR1020137019290A patent/KR101842098B1/ko active IP Right Grant
- 2011-12-16 CN CN201180061368.3A patent/CN103429585B/zh active Active
- 2011-12-16 RS RS20160779A patent/RS55165B1/sr unknown
- 2011-12-16 JP JP2013545217A patent/JP6007189B2/ja active Active
- 2011-12-16 US US13/995,803 patent/US9073892B2/en active Active
- 2011-12-20 AR ARP110104813A patent/AR084507A1/es active IP Right Grant
-
2013
- 2013-06-13 IL IL226912A patent/IL226912A/en active IP Right Grant
- 2013-07-19 ZA ZA2013/05483A patent/ZA201305483B/en unknown
-
2014
- 2014-05-30 HK HK14105096.6A patent/HK1191938A1/xx unknown
-
2016
- 2016-09-02 HR HRP20161127TT patent/HRP20161127T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2822166C (en) | 2019-10-29 |
LT2655357T (lt) | 2016-10-10 |
SG191205A1 (en) | 2013-07-31 |
AU2011347711A1 (en) | 2013-08-01 |
EA201300730A1 (ru) | 2013-12-30 |
CA2822166A1 (en) | 2012-06-28 |
PT2655357T (pt) | 2016-09-28 |
CN103429585B (zh) | 2015-07-08 |
EA023544B1 (ru) | 2016-06-30 |
HK1191938A1 (en) | 2014-08-08 |
KR20130133252A (ko) | 2013-12-06 |
ES2592713T3 (es) | 2016-12-01 |
BR122021014375B1 (pt) | 2021-11-30 |
BR112013015460A2 (pt) | 2016-09-20 |
US20130274241A1 (en) | 2013-10-17 |
PL2655357T3 (pl) | 2016-12-30 |
IL226912A (en) | 2017-01-31 |
BR112013015460B1 (pt) | 2022-01-25 |
WO2012084704A1 (en) | 2012-06-28 |
KR101842098B1 (ko) | 2018-03-26 |
AU2011347711B2 (en) | 2017-02-02 |
HUE029617T2 (en) | 2017-03-28 |
ZA201305483B (en) | 2014-06-25 |
MX2013007149A (es) | 2013-10-30 |
EP2655357B1 (en) | 2016-06-22 |
JP6007189B2 (ja) | 2016-10-12 |
CN103429585A (zh) | 2013-12-04 |
US9073892B2 (en) | 2015-07-07 |
AR084507A1 (es) | 2013-05-22 |
EP2655357A1 (en) | 2013-10-30 |
JP2014500286A (ja) | 2014-01-09 |
HRP20161127T1 (hr) | 2016-11-18 |
SI2655357T1 (sl) | 2016-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201305483B (en) | Indazolyl triazole derivatives as irak inhibitors | |
HK1259135A1 (zh) | Vmat2的苯並喹啉酮抑制劑 | |
ZA201204959B (en) | Pyrazole derivatives as jak inhibitors | |
IL237581B (en) | Derivatives of 6-oxo-pyrazinopyrrolopyrimidines | |
IL221823A (en) | Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors | |
EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
ZA201207636B (en) | Heteroaryl imidazoline derivatives as jak inhibitors | |
IL219916A0 (en) | Imidazopyridine derivatives as jak inhibitor | |
EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
ZA201208125B (en) | Pyrazole compounds as jak inhibitors | |
EP2615916A4 (en) | CONDENSED PYRAZOLE DERIVATIVES AS NEW ERK INHIBITORS | |
ZA201304282B (en) | Pyrazole derivative | |
ZA201206456B (en) | Uses of dgati inhibitors | |
HK1166077A1 (en) | Resorcinol derivatives as hsp90 inhibitors hsp90 | |
HUE044301T2 (hu) | Benzodioxol-származékok, mint foszfodiészteráz inhibitorok | |
EP2654748A4 (en) | INDAZONE DERIVATIVES AS ERK HEMMER | |
GB201009853D0 (en) | HSP90 inhibitors | |
HRP20150939T1 (en) | Pyrazole derivatives useful as aldosterone synthase inhibitors | |
HK1180971A1 (zh) | 吡唑化合物 | |
EP2527343A4 (en) | HETEROCYCLIC CONNECTION WITH AN AOLA GROUP | |
PL2558462T3 (pl) | Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1 | |
GB201018597D0 (en) | Inhibitors | |
GB201006605D0 (en) | Novel inhibitors | |
GB201003936D0 (en) | Novel inhibitors |